Hemab's CEO said the phase 3 Glansman study uses a single-arm design with approximately 75 patients. The company has more than $400 million in cash, with runway well into 2029.
COAG · Hemab Therapeutics Holdings, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
The closing range uses available history since May 1, 2026; less than a full year is stored.
Up next
Latest documents
Hemab Therapeutics Holdings, Inc. initiated SOLARA Phase 3 of sutacimig in November 2026. Its nine-month net loss was $74.1 million, while cash and marketable securities totaled $430.2 million as of September 30, 2026, funding operations into 2029.
HEMAP initiated SOLARA, its first Phase III trial, and reported $430.2 million in cash, cash equivalents and marketable securities as of September 30. The company expects cash to fund operations into 2029.
Hemab Therapeutics began SOLARA, a Phase 3 trial of subcutaneous prophylactic sutacimig in Glanzmann thrombasthenia. It reported $430.2 million in cash, cash equivalents, and marketable securities as of September 30, 2026, and a $27.3 million quarterly net loss.
Hemab Therapeutics Holdings, Inc. elected Keli Walbert as a Class I director and Audit Committee member, effective immediately. Her term expires at the 2027 annual meeting, and she will receive an option to purchase 36,000 shares vesting through the third anniversary.
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q3 FY26 earnings call · Nov 10, 2026TL;DR. Hemab initiated SOLARA, the first pivotal trial of a subcutaneous prophylactic treatment in Glanzmann thrombasthenia, reported positive initial clinical data for sutacimig in Factor VII deficiency and positive HMB-002 clinical data, and expects cash to fund operations into 2029. Concerns include rising quarterly expenses and losses, lower cash, Grade 2 thromboembolic events, and regulatory risks surrounding SOLARA’s single-arm design.
- + SOLARA is the first pivotal trial of a subcutaneous prophylactic treatment in Glanzmann thrombasthenia.
- + Initial Factor VII deficiency data showed more than 50% shortening of prothrombin time in both participants and sustained approximately 5x accumulation of endogenous FVII(a) in the participant with PK/PD data available to date.
- + VELORA Pioneer data demonstrated proof of mechanism, including a ≥2.4-fold peak increase in VWF and FVIII and durability supporting potential monthly dosing.
- + Eight of nine evaluable HMB-002 patients had zero treated bleeds during the 28 days after dosing, with mean ATBR of 1.6 versus 20.1 before treatment.
- + Hemab dosed the first participant in the Phase 1 trial of HMB-003 for heavy menstrual bleeding.
- + Hemab expects its current cash resources to fund operating expenses and capital expenditure requirements into 2029.
- − Research and development expense increased to $24.6 million in Q3 2026 from $14.6 million in the prior-year quarter.
- − General and administrative expense increased to $5.1 million in Q3 2026 from $2.5 million in the prior-year quarter.
- − Net loss increased to $27.3 million in Q3 2026 from $17.1 million in the prior-year quarter.
- − Cash, cash equivalents, and marketable securities declined to $430.2 million at September 30, 2026 from $457.5 million at June 30, 2026.
- − Three participants in higher-exposure cohorts or with multiple risk factors experienced Grade 2 thromboembolic events.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents, and marketable securities | $430.2M | as of September 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COAG
this stock
Hemab Therapeutics Holdings, Inc.
|
$1.83B | — | — | — | 7.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 15
Hemab's CEO said the phase 3 Glansman study uses a single-arm design with approximately 75 patients. The company has more than $400 million in cash, with runway well into 2029.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COAG | -0.5% | +10.8% | +37.4% | -5.6% | — |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | +3.4% | +16.3% | +40.8% | -2.2% | — |